

Based on the "Stock Detailed Analysis Report" for SUNPHARMA.NS generated on 2026-01-03, here is the positional trading analysis.

Step 1: Audit the Data

- * **Data Present:**
 - * Daily Price Action (3-Year and 1-Year views).
 - * Moving Averages (EMA 20, 50, 200) and Crossover status.
 - * Relative Strength (RS) against the sector and index.
 - * Momentum Indicators (RSI, MACD).
 - * Volatility Indicators (Bollinger Bands, ATR, Squeeze).
 - * Trend Indicators (Supertrend).
 - * Fundamental Snapshots (Revenue, EPS, Valuation).
- * **Data Missing:**
 - * Weekly/Monthly specific charts (though inferred from long-term daily charts).
 - * Detailed Volume Profile or Delivery data (though basic Volume MA is present).
- * **Confidence Level: High.**
 - * The report is comprehensive and covers trend, momentum, volatility, and fundamentals.
- * *Note: The report date is January 3, 2026. This analysis treats the data as current to that simulated date.*

Step 2: Analyze the Setup

- * **Price Structure & Trend:**
 - * **Long-Term:** **Bullish**. The price (1728) is above the 200 EMA (1705), indicating the primary trend is still upward.
 - * **Intermediate-Term:** Corrective/**Bearish**. The price is trading below the EMA 20 (1747) and EMA 50 (1741). The Supertrend (Page 10) generated a Sell signal on Dec 18, 2025.
 - * **Pattern:** The stock is experiencing a pullback from highs of ~1900. It is currently sandwiched between overhead resistance (EMA 20/50) and major support (EMA 200).
- * **Momentum & Confluence:**
 - * **Bearish Momentum:** MACD is negative and below the signal line (Page 12). RSI is at 42 (Page 16), which is weak but not yet oversold (<30).
 - * **Support Zone:** The 200 EMA is at **1705**. The Lower Bollinger Band is at **1693**. This creates a strong "confluence zone" of support between 1690-1705.
 - * **Relative Strength:** The stock is lagging. The RS Score is 48.4 (Neutral) and the RS line is trending down, indicating it is underperforming the Pharma index in the short term.
- * **Verdict:** The stock is in a "No Trade Zone." It is falling towards major support but has not shown signs of stabilization or reversal yet. Buying now is "catching a falling knife" before the floor (200 EMA) is tested.

Step 3: Formulate the Recommendation

Recommendation: NO

Do not enter at the current market price (1728.00). The short-term trend is down, and momentum is negative. You should wait for the price to test the 200 EMA support and show a reversal, OR reclaim the short-term moving averages.

Conditional Plan (Watchlist):

Since the long-term trend is up, this is a high-probability "dip buy" setup *if* specific conditions are met.

- * **Condition to Buy:**
 - * **Aggressive:** A daily candle touching the **1700-1710** zone (200 EMA) followed by a bullish candlestick pattern (e.g., Hammer or Green Engulfing).

* **Conservative (Preferred):** A daily Close above the **EMA 20 (approx. 1750)**. This confirms the short-term correction is over and momentum has shifted back to the upside.

* **Entry Price:** **INR 1755** (Buy Stop order just above the EMA 20/50 cluster to confirm strength).

* ****Stop Loss**:** **INR 1685** (Daily close basis).

* **Rationale:** This is below the critical 200 EMA (1705) and the Lower Bollinger Band (1693). If this level breaks, the long-term trend is violated.

* ****Take Profit**:** **INR 1920 - INR 1950**

* **Rationale:** Re-test of the recent swing highs (~1920) and the Analyst Target Price (1951).

* **Risk/Reward:** Approx 1:2.4 (Risking ~4% to make ~9.5%).

Summary: The stock is fundamentally strong but technically weak in the short term. Patience is required to let it find support at the 200 EMA (1705) before initiating a long position.

News & Analyst Targets

As a stock research analyst, I have gathered the latest information on **Sun Pharmaceutical Industries Ltd. (SUNPHARMA)** for the week ending **January 3, 2026**.

1) Latest News for SUNPHARMA (This Week)

* **Trading Window Closure:** Effective **January 1, 2026**, Sun Pharma has closed its trading window for insiders. This is a routine compliance measure ahead of the declaration of its Q3 FY26 financial results. The window will remain closed until 48 hours after the results are announced.

* **Leqselvi Launch Delays:** Reports highlight that while Sun Pharma received US FDA approval for its alopecia drug **Leqselvi (deuruxolitinib)**, the commercial launch remains indefinitely delayed due to ongoing patent litigation. This continues to be a key point of discussion for investors monitoring the company's US specialty portfolio.

* **Ilumya Launch in India:** The company recently announced the launch of **Ilumya (tildrakizumab)** in India. This drug, used for treating moderate-to-severe plaque psoriasis, has been a key driver in its global specialty business and is now available for the domestic market.

* **Stock Price Volatility:** The stock has seen mixed trading sessions this week (trading around **INR 1,720 - INR 1,730** levels), reacting to broader market trends and digesting recent regulatory updates regarding its manufacturing facilities.

2) Brokerage Upgrades & Downgrades

* **Choice Equity Broking (Fresh Recommendation):** On **December 30, 2025**, Choice Equity recommended a **BUY** rating on Sun Pharma with a target price of **INR 1,825**, citing a potential upside of approximately 6% from the trading price at that time.

* **MarketsMojo (Downgrade):** In mid-December, the research platform adjusted its rating from "Strong Buy" to **Buy**, reflecting a slightly more cautious but still positive stance due to recent sector headwinds.

* **Jefferies & Nuvama (Maintained):** Major foreign brokerages have largely maintained their stance from late 2025. **Jefferies** remains bullish (Buy) with a high target, while **Nuvama** has maintained a cautious "Hold" rating, citing valuation and execution risks.

3) Other News Impacting SUNPHARMA

* **US FDA 'OAI' Classification (Negative Impact):** In mid-December, the US FDA classified Sun Pharma's **Baska manufacturing facility** as **"Official Action Indicated" (OAI)**. This classification implies that the FDA found objectionable conditions that require regulatory or administrative action. This outcome typically delays product approvals from the specific site until the issues are resolved.

* **Semaglutide Legal Ruling (Mixed Impact):** In a significant legal development late last month, the **Delhi High Court** permitted Sun Pharma to **manufacture and export** its generic version of the popular weight-loss drug **Semaglutide**. However, the court **barred domestic sales** in India until the expiry of Novo Nordisk's patent in **March 2026**. This is seen as a partial win, allowing the company to tap into export markets immediately while preparing for a domestic launch later.

4) Analyst Targets for SUNPHARMA

The following table summarizes the latest price targets from major brokerage firms and the analyst community. The stock is currently trading near **INR 1,720**.

Brokerage / Firm	Rating	Target Price (INR)	Sentiment
---	---	---	
JM Financial	BUY	**2,115**	Bullish
Jefferies	BUY	**2,070**	Bullish
Consensus Average		BUY	**1,950** Positive
ICICI Securities	BUY	**1,895**	Positive
Nuvama	HOLD	**1,830**	Cautious
Choice Equity	BUY	**1,825**	Positive
Motilal Oswal	BUY	**1,800***	Moderate

**Target based on previous quarter notes; retained in recent consolidations.*

Analyst Summary: The consensus among the analyst community remains largely **positive**, with an average target price indicating an upside of roughly **10-13%** from current levels. The primary bullish thesis relies on the ramp-up of the specialty business (Illumya, Winlevi), while the "Hold" ratings typically flag regulatory risks (FDA observations) and rich valuations.

Stock Detailed Analysis Report

SUNPHARMA.NS

Current Price: ₹1728.00

Generated: 2026-01-03 12:44

SUNPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	8.97%	10.64%
Net Income	Yes	No	14.12%	49.47%
ROE	Yes	No	0.61%	30.45%
EPS	Yes	No	14.29%	49.67%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	7.57%	2.54%
Net Income	No	5.99%	-4.31%
ROE	No	-32.32%	-32.32%
EPS	Yes	-4.72%	1.45%

SUNPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index: ^CNXPHARMA

Sector: Pharma

Classification: Neutral

RS Score: 48.4/100

:

== RS RATIOS ==:

1M RS: 0.955 [Neutral]

3M RS: 0.983 [Neutral]

6M RS: 0.997 [Neutral]

1Y RS: 0.911 [Neutral]

:

== TURNAROUND ANALYSIS ==:

Turnaround Status: Not Detected

:


SIGNAL CRITERIA::

X Emerging RS: Not accelerating


✓ Medium-term Lagging: 6M=0.997, 1Y=0.911 (≤ 1.0)

✓ Performance Improving: 3M (+5.6%) > 6M (+3.0%)


Relative Strength Analysis: SUNPHARMA.NS vs ^CNXPHARMA
Classification: Neutral
Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



SUNPHARMA.NS - EMA Crossover Summary

EMA 20:	1747.16
EMA 50:	1741.33
EMA 200:	1705.35
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-18 00:00:00
Golden Cross Price:	1758.80

SUNPHARMA.NS EMA Crossover Analysis



SUNPHARMA.NS - Bollinger Bands Summary

Current Price:	1728.00
Upper Band:	1820.79
Middle Band (SMA 20):	1757.29
Lower Band:	1693.80
%B:	0.2693
Band Width:	0.0723
Status:	Lower Half
Signal:	None
Recent Signal 1:	Sell Signal at 2025-12-01 00:00:00

SUNPHARMA.NS Bollinger Bands (20, 2) Analysis



SUNPHARMA.NS - Supertrend Summary

Status:

DOWNTREND (Sell)


Supertrend Value:

1788.19

Signal Identified On:

2025-12-18

Supertrend Analysis for SUNPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




SUNPHARMA.NS - MACD Summary

MACD Line:	-12.59
Signal Line:	-6.41
Histogram:	-6.19
Trend:	Bearish
Momentum:	Weakening
Signal:	None

SUNPHARMA.NS Price






SUNPHARMA.NS MACD (12, 26, 9)



SUNPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.0723
ATR:	22.5500
Total Signals:	23
Signal 1:	BB Squeeze at 2025-12-16 00:00:00 (Price: 1781.30)
Signal 2:	BB Squeeze at 2025-12-17 00:00:00 (Price: 1792.90)
Signal 3:	ATR Contraction at 2025-12-31 00:00:00 (Price: 1719.70)
Signal 4:	ATR Contraction at 2026-01-01 00:00:00 (Price: 1721.10)
Signal 5:	ATR Contraction at 2026-01-02 00:00:00 (Price: 1728.00)


SUNPHARMA.NS - Volatility Squeeze Analysis



SUNPHARMA.NS - RSI-Volume Summary

Current RSI:	42.06
Current Volume:	974123
Volume MA 20:	1798664
Bullish Divergences:	2
Bearish Divergences:	3
Bullish Div 1:	Date: 2024-01-17 00:00:00, Price: 1299.00
Bullish Div 2:	Date: 2025-06-04 00:00:00, Price: 1664.90
Bearish Div 1:	Date: 2024-04-01 00:00:00, Price: 1629.25
Bearish Div 2:	Date: 2025-07-30 00:00:00, Price: 1733.80

SUNPHARMA.NS RSI-Volume Divergence Analysis



Trendlyne Snapshot - SUNPHARMA_main

Markets STARFOLIO Alerts F&O MF Reports Screeners Subscribe Superstars Portfolio Watchlist Insider Trades Results Data Downloader More Search Stock, IPO, MF India A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / SUN PHARMACEUTICAL INDUSTRIES LTD.

Sun Pharmaceutical Industries Ltd. ⓘ

NSE: SUNPHARMA | BSE: 524715
Sun Pharmaceutical Live Share Price Today, Share Analysis and Chart

■ ■ ■ Mid-range Performer ⓘ ○ In 10 Starfolio Baskets

1728.00 6.90 (0.40%) **1.0M** NSE+BSE Volume
NSE 02 Jan, 2026 3:31 PM (IST)

ABOUT Incorporated in 1993, Sun Pharmaceutical Industries (Sun Pharma) is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and Active Pharmaceutical Ingredients (APIs). It offers innovative ... [Read More](#)

Watchlist Portfolio Alert My Notes TRADE STOCK

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

Durability score ⓘ **65.0 /100** Valuation Score ⓘ **31.5 /100** Momentum Score ⓘ **48.4 /100** Analyst Price Target ⓘ **1,951**
High Financial Strength Mid Valuation Technically Neutral
Mid-range Performer These stocks have strong quality. Their reasonable financials and technicals make them potential investments. View Similar Embed DVM

Analyst Price Target ⓘ **1,951**
1Yr Price target upside is 13%

FORECASTER DVM Key Metrics Price Chart Forecaster Financials Technicals Shareholding Deals Documents Corporate actions Company Profile X

Check Before You Buy **60.9% Pass in checklist** VIEW FULL CHECKLIST

PE Valuation Check Right Now ⓘ Undervalued 25.5% 1 Year Forward ⓘ Undervalued 40.3%

INSIGHT Sun Pharmaceutical is undervalued at both current PE and future earnings estimates.

SWOT Analysis ⓘ

Sun Pharmaceutical Key Metrics

ROE Ann. % > Above industry Median **15.1** Broker Average Target > 11.19% upside **1,921.38** Market Capitalization > Market Leader **414,605.1** Price to Book > Above industry Median **5.3**

Trendlyne Snapshot - SUNPHARMA_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [A](#)

Search Stock, IPO, MF [India](#)

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [SUN PHARMACEUTICAL INDUSTRIES LTD.](#)

Sun Pharmaceutical Industries Ltd. [ⓘ](#)

NSE: SUNPHARMA | BSE: 524715
Mid-range Performer [ⓘ](#) In 10 Starfolio Baskets

1728.00 6.90 (0.40%) **1.0M** NSE+BSE Volume
NSE 02 Jan, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes [TRADE STOCK](#)

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

Sun Pharmaceutical - SUNPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 38 analysts

Sun Pharmaceutical has a share price target of Rs 1951, revenue growth forecast of 9.1%, and profit growth estimate of 2.7% for FY26, based on top 38 analyst calls.

Sun Pharmaceutical FORECASTER - Analyst Estimates [ⓘ](#)

[FORECASTER DASHBOARD](#) [↗](#)

